

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE CIRCULAR OF THE ANNUAL GENERAL MEETING

Reference is made to the circular of the annual general meeting of CStone Pharmaceuticals (the “**Company**”) dated 1 June 2026 (the “**AGM Circular**”). Unless otherwise defined, capitalised terms used herein shall have the same meaning as defined in the AGM Circular.

PROPOSED GRANTS OF SHARE OPTIONS AND RSUS TO A DIRECTOR AND CHIEF EXECUTIVE OFFICER UNDER THE POST-IPO ESOP AND THE POST-IPO RSU SCHEME

As disclosed in the AGM Circular, on 23 January 2026, the Company proposed the conditional grants of 7,000,000 Share Options under the Post-IPO ESOP and 4,270,000 RSUs under the Post-IPO RSU Scheme to Dr. Yang, an executive Director and the Chief Executive Officer, subject to (i) acceptance of such Share Options and RSUs by Dr. Yang; and (ii) approval by the Shareholders at the AGM (the “**Proposed Grants**”). The Company would like to provide the following supplementary information in relation to the Listing Rules implications of the Proposed Grants.

The Grant of RSUs is funded by new Shares. Pursuant to Rule 17.04(2) of the Listing Rules, where any grant of awards (excluding grant of options) to a Director (other than an independent non-executive Director) or chief executive of the Company, or any of their associates would result in the Shares issued and to be issued in respect of all awards granted (excluding any awards lapsed in accordance with the terms of the scheme) to such person in the 12-month period up to and including the date of such grant, representing in aggregate over 0.1% of the relevant class of shares in issue (excluding treasury shares), such further grant of awards must be approved by independent Shareholders in general meeting with such grantee, his/her associates and all core connected persons of the Company abstaining from voting in favor at such general meeting.

As the proposed grant of 4,270,000 RSUs would result in the Shares issued and to be issued in respect of all RSUs granted (excluding any awards lapsed in accordance with the terms of the scheme) to Dr. Yang in the 12-month period up to and including the date of grant, representing in aggregate over 0.1% of the Shares in issue (excluding treasury shares), the Grant of RSUs to Dr. Yang shall be subject to the approval by independent Shareholders pursuant to Rule 17.04(2) of the Listing Rules.

As at the Latest Practicable Date disclosed in the AGM Circular, to the best knowledge of the Directors after making reasonable enquiry, Dr. Yang was interested in 71,833,142 Shares including (i) 19,744,808 Shares beneficially held by Dr. Yang under his own name; (ii) 49,639,959 share options granted to him under the Post-IPO ESOP (not including the 7,000,000 Share Options conditionally granted to Dr. Yang), subject to the vesting and other conditions of those share options; and (iii) 2,448,375 RSUs granted to him under the Post-IPO RSU Scheme (not including the 4,270,000 RSUs conditionally granted to Dr. Yang), subject to vesting conditions, representing in aggregate approximately 4.49% of the total issued Shares of the Company (excluding treasury Shares). None of Dr. Yang's respective associates, as prescribed under the Listing Rules, holds any Shares.

As at the Latest Practicable Date disclosed in the AGM Circular, to the best knowledge of the Directors after making reasonable enquiry, other than Dr. Yang, core connected persons of the Company who are Shareholders include (i) WuXi Healthcare Ventures II, L.P., a substantial shareholder of the Company which directly held 173,381,444 Shares, representing approximately 10.83% of the total issued Shares of the Company (excluding treasury Shares). WuXi Healthcare Ventures II, L.P. is a limited partnership established under the laws of Cayman Islands managed by its sole general partner, WuXi Healthcare Management, LLC, a Cayman Islands exempted company in which each of its five members holds an equal share of equity interest; (ii) Dr. Wei Li ("**Dr. Li**"), a non-executive Director and the Chairman, who was interested in 2,000,000 Shares including 979,159 Shares beneficially held by Dr. Li under his own name, 500,004 share options granted to him under the Post-IPO ESOP and 520,837 RSUs granted to him under the Post-IPO RSU Scheme, representing approximately 0.12% of the total issued Shares of the Company (excluding treasury Shares); (iii) Mr. Edward Hu ("**Mr. Hu**"), a non-executive Director, who was interested in 3,471,000 Shares including 1,950,163 Shares beneficially held by Mr. Hu under his own name, 1,000,000 share options granted to him under the Post-IPO ESOP and 520,837 RSUs granted to him under the Post-IPO RSU Scheme, representing approximately 0.22% of the total issued Shares of the Company (excluding treasury Shares); (iv) Mr. Kenneth Walton Hitchner III ("**Mr. Hitchner**"), a non-executive Director, who beneficially held 2,113,481 Shares under his own name, representing approximately 0.13% of the total issued Shares of the Company (excluding treasury Shares); and (v) Ms. Fang Xie ("**Ms. Xie**"), an independent non-executive Director, who beneficially held 8,500 Shares under her own name.

To the extent the Company is aware and having made all reasonable enquiries, Dr. Yang, WuXi Healthcare Ventures II, L.P., Dr. Li, Mr. Hu, Mr. Hitchner and Ms. Xie, holding in aggregate 252,807,567 Shares (comprising issued Shares, share options and RSUs), representing approximately 15.79% of the total issued Shares of the Company (excluding treasury Shares) as at the Latest Practicable Date disclosed in the AGM Circular, shall abstain from voting in favor on the proposed resolution in relation to the Proposed Grants at the AGM.

The above supplementary information is provided solely to facilitate the Shareholders' consideration of the proposed resolution and does not amend the substance of the proposed resolution, the Proposed Grants, or the business to be transacted at the AGM or affect other information contained in the AGM Circular. Save as disclosed above, all other information contained in the AGM Circular, the notice of the AGM and the proxy form for the AGM remains unchanged.

By Order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Suzhou, the People's Republic of China, 16 June 2026

As at the date of this announcement, the Board comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III and Mr. Edward Hu as non-executive directors, and Mr. Kenneth Howard Jarrett, Ms. Fang Xie and Ms. Catherine Yen as independent non-executive directors.